SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude rallies on fears that escalating Middle East conflict and attacks on tankers and energy infrastructure could disrupt oil supplies, with traders also citing tight inventories. The community is split between bulls expecting further gains and bears who see a crowded, speculation-driven war premium that could unwind if diplomacy advances or supply concerns ease.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention after a sharp selloff across AI infrastructure and neocloud stocks, fueled by worries about financing costs, debt, and whether AI buildout spending will earn adequate returns. Traders are split on whether the oversold rebound signals stabilization or is a bull trap, with some arguing Nebius is better positioned than more debt-heavy peers.

iShares Trust - iShares Russell 2000 Index Fund

iShares Russell 2000 ETF

Small caps are under pressure amid hotter inflation readings and concerns that interest rates may stay higher, with traders noting the Russell 2000s sensitivity to borrowing costs and its technical weakness. Some see oversold conditions and sector rotation as support for a rebound, while others expect further downside if key support fails.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSCIs new index rules have raised the possibility that Strategy could be removed from major benchmarks, fueling concerns about forced passive-fund selling and adding pressure amid Bitcoin volatility. Traders are split between expecting further downside and buying the dip, with dilution and the companys preferred-stock buyback strategy also drawing criticism; removal has not been confirmed.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStops reminder that its shareholder warrants are nearing expiration is driving attention, with traders focused on whether the shares can rise above the exercise price before the deadline. Bears expect the warrants to expire worthless, avoiding dilution, while bulls speculate that Ryan Cohen may take action to lift the stock or extend the deadline.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is drawing attention amid a volatile rebound after a sharp semiconductor selloff, as traders debate whether AI infrastructure spending can generate sufficient returns and whether debt risks at companies such as CoreWeave signal broader trouble. Bears see more downside if capex and financing concerns persist, while bulls view the pullback as overdone and expect upcoming earnings and guidance to reinforce AI-chip demand.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows is being linked to concerns about Trumps political standing ahead of the midterms and doubts about the companys business prospects, including Truth Social engagement. The discussion is overwhelmingly bearish, though some traders see a potential bounce or short squeeze.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a sharp, prolonged pullback and a wider semiconductor selloff, with traders debating whether concerns about AI spending, financing, and returns signal a broader downturn. Many blame CEO Hock Tans comments likening AI investing to gambling for worsening sentiment, while others view the selloff as a buying opportunity.

The Coca-Cola Co. engages in the manufacturing and marketing of non-alcoholic beverages. It operates through the following segments: Europe, Middle East and Africa, Latin America, North America, Asia Pacific, Global Ventures, and Bottling Investments. The company was founded by Asa Griggs Candler on May 8, 1886 and is headquartered in Atlanta, GA.

Coca-Cola Co

Coca-Colas new U.S. beverage partnership with KFC, replacing Pepsi at its restaurants, is drawing attention alongside KOs recent breakout and strength versus weaker tech stocks. Traders are broadly bullish on the momentum and defensive appeal, though some see the shares as stretched and expect resistance or a pullback.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

A sharp, volatile pullback has investors focused on whether CLS can hold support, with some traders buying the dip while others expect further declines. The selloff is being weighed against optimism about AI-infrastructure demand and an upcoming earnings report, though traders disagree on whether that optimism is already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that senior management will participate in a fireside chat at the Wells Fargo 21st Annual...

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported recent business highlights and financial results for the second quarter ended June 30...

VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know

Viridian enters the commercial stage after FDA approval of Lumvoa for thyroid eye disease, with expanded labeling and plans for an immediate U.S. launch.

Viridian Secures First FDA Approval, Sets Up Challenge To Amgen's Tepezza For Thyroid Eye Disease

FDA approves Viridian Therapeutics' Lumvoa for thyroid eye disease. Immediate commercial launch scheduled with full patient support.read more...

4 Sizzling Biotech and Healthcare Companies Reporting Strategic Milestones

As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. $UPC, $NTHI, $DCOY, $VRDN

Futures Rise As Dip-Buyers Lift Tech Stocks

Futures Rise As Dip-Buyers Lift Tech Stocks

 US equity futures are higher led by Tech as Mag7 leads the group higher and points to a reversal of last week's profit-taking, as traders position for the end of the first half. A shortened week will likely focus on a speech from the Fed's...

Concentrix, AeroVironment And 3 Stocks To Watch Heading Into Monday

U.S. stock futures up, watch Concentrix Corp, Lantheus Holdings, AeroVironment, Viridian Therapeutics, Universe Pharmaceuticals for earnings and news.read more...

VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval  

Equity

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 


Viridian Therapeutics Announces U.S. FDA Approval and Launch of Lumvoa (veligrotug-vvze) for the Treatment of Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa (veligrotug-vvze...

Viridian Therapeutics to Participate in Upcoming June Investor Conferences

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that members of its management team will participate in the following upcoming investor...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Bullish Sentiment

<ul class="summary-bullets"><li>Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</li><li>Physicians can begin prescribing Lumvoa immediately, the company said.</li><li>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems.</li></ul><p>Shares of Viridian Therapeutics Inc (VRDN) jumped 6% after-hours on Friday after the U.S. Food and Drug Administration approved its drug Lumvoa for the treatment of thyroid eye disease.</p><p>The drug is now available by prescription and marks the company’s first approved medicine and first commercial product.</p><h2 class="st-heading-2">New Option For Active And Chronic Disease</h2><p>TED is a rare autoimmune condition that causes painful inflammation and swelling around the eyes, leading to bulging, double vision, discomfort, and in some cases, vision problems. Lumvoa is the first treatment approved for patients with TED regardless of whether the disease is in its active (early) or chronic (long-term) stage.</p><h2 class="st-heading-2">Strong Results In Key Trials</h2><p>The approval was based on two large late-stage studies — THRIVE in active TED and THRIVE-2 in chronic TED. In both trials, Lumvoa met all primary and secondary goals. Patients saw rapid reductions in eye bulging and double vision, with improvements beginning as early as three weeks. The drug is given as five intravenous infusions over 12 weeks.</p><h2 class="st-heading-2">Immediate Launch And Patient Support</h2><p>Physicians can begin prescribing Lumvoa immediately, the company said. Viridian has launched ViridianCares, a patient support program that offers insurance navigation, financial assistance, and dedicated support staff to help eligible patients access treatment.</p><h2 class="st-heading-2">Company And Expert Reaction</h2><p>“This approval represents a major step forward for people living with thyroid eye disease,” said Steve Mahoney, President and CEO of Viridian. “Lumvoa was designed with patients in mind and addresses a clear need across the full spectrum of the disease.”</p><p>In addition to Lumvoa, Viridian is advancing VRDN-003, a subcutaneous anti-IGF-1R antibody designed for self-administration via autoinjector. The company recently reported positive topline results from two pivotal late-stage trials in active and chronic thyroid eye disease.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around VRDN stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><p>A Stocktwits user cheered the news as “massive” and recommended watching the stock next week.</p><p><stembedurl>https://www.stocktwits.com/Daniel_2025/message/657668888</stembedurl></p><p>According to data from Koyfin, 16 of the 17 analysts covering VRDN stock rate it ‘Buy’ or higher, while one rates it ‘Hold.’ The 12-month average price target on the stock is $33.94, representing a potential upside of about 90% from the last closing price.</p><p><a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 42% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/upc-stock-surges-after-hours-whats-driving-the-rally/cZ12TA7R7WB">UPC Stock Surges 288% After Hours — What’s Driving The Rally?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Viridian Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

The FDA approved Viridian’s Lumvoa for the treatment of thyroid eye disease. 

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

SpaceX

Netflix Inc

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Stocktwits Polls

$VRDN RBC Capital raised the firm's price target on Viridian Therapeutics to $38 from $36 and keeps an Outperform rating on the shares. The firm has spoken to 6 TED key opinion leaders who collectively see about 2,000 TED patients about Lumvoa's launch, noting that it is pleasantly surprised to hear that 3/6 of the physicians have written at least 1 or more Rx, and 2/6 have reported infusing at least 1 patient so far, suggesting some payer access has gone smoothly, the analyst tells investors in a research note. While it is still early days for Lumvoa, the evidence of early adopters is encouraging suggesting physicians are eager to gain experience with Lumvoa and see how it compares to Tepezza in terms of efficacy/safety, the firm added

Tom Dorsey

$VRDN how do you guys feel about the “Enspryng” product from Roche that has been FDA approved
Is it gonna hurt Viridian or not? How so?

Emre1990

$VRDN A complete shakeout of weak hands. Looks like Point72 and other institutions are officially bagholders now too. And that daily volume is totally screaming "institutional exit"! 🙄 There’s no classic bull vs. bear battle going on here. (Feel free to check my previous posts). Q4 is shaping up to be fun...

onur can

$VRDN just want to get your ideas the advantage Lumvoa has over Tepezza? Is it going to take share away from it or both can grow in their market.  What's the expected sales for Lumvoa for Q3?

jack p

$VRDN Any thoughts on why this is down 6 plus percent today?  I do not see any news out there

Mark

$VRDN Just rising rates??? RBC upped price target saying their channel checks indicate Lumvoa launch is stronger than they anticipated.

Feed

News

Sentiment

Earnings

Fundamentals

Info

VRDN Viridian Therapeutics Inc

Fundamentals

Latest VRDN News